
|Videos|September 10, 2015
Biosimilars Poised to Impact Specialty Pharmacy
Author(s)Davy James, Managing Editor
Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.
Advertisement
Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
2
Beyond the Transplant Center: IV Therapy in the Community
3
Incorporating Patient-Reported Symptoms into Treatment Plans
4
Safety Monitoring Protocols During Transitions of Care
5



































































































